Strategic partnership Invetx has a history of strategic collaborations with industry leaders (Absci, Nona Biosciences, Boehringer Ingelheim) and is now under Dechra, highlighting a channel through which sales teams can position complementary biotherapeutics, AI-enabled drug discovery, and animal health platforms for co-development opportunities.

Animal health focus The company specializes in protein-based therapeutics for cats and dogs with a vision to transform veterinary care, signaling strong cross-sell potential to veterinary clinics, pet insurers, and specialty veterinary distributors seeking innovative mAb therapies and longer half-life biologics.

GenAI advantage Recent partnerships emphasize generative AI and Harbour Mice platforms, presenting opportunities to offer AI-enabled discovery services, rapid candidate generation, and accelerated IND timelines to biotech firms and sponsors looking to de-risk early development in animal health.

Financial backing With substantial funding and a revenue range of 1–10 million and an $86 million funding runway, there is appetite for strategic collaborations, co-development deals, and licensing agreements to expand portfolio capabilities and scale manufacturing for select animal health programs.

Broad network access Invetx leverages an extensive network of veterinary scientists, clinicians, and industry experts, offering a gateway for partners to access a proven ecosystem for advisory support, clinical insights, and accelerated regulatory pathways in animal health therapeutics.